C07D237/28

FUSED RING COMPOUND AND APPLICATION THEREOF

Disclosed is a fused ring compound and an application thereof. Disclosed is a fused ring compound represented by formula I, a pharmaceutically acceptable salt, a stereoisomer, a tautomer, an isotope compound, a crystal form, a nitrogen oxide, a solvate, or a solvate of the pharmaceutically acceptable salt thereof. The fused ring compound of the present invention has high P2X4 antagonistic activity, excellent selectivity, low toxicity and excellent metabolic stability.

##STR00001##

FUSED RING COMPOUND AND APPLICATION THEREOF

Disclosed is a fused ring compound and an application thereof. Disclosed is a fused ring compound represented by formula I, a pharmaceutically acceptable salt, a stereoisomer, a tautomer, an isotope compound, a crystal form, a nitrogen oxide, a solvate, or a solvate of the pharmaceutically acceptable salt thereof. The fused ring compound of the present invention has high P2X4 antagonistic activity, excellent selectivity, low toxicity and excellent metabolic stability.

##STR00001##

COMPOUNDS AND THEIR USE

The specification generally relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where R.sup.1, R.sup.2A, R.sup.2B, R.sup.2C, R.sup.2D, W, X, Y, and Z have the meanings defined herein. Such compounds are useful in inhibiting NLRP3 inflammasome activity and may be useful as therapeutic agents. The specification also relates to the use of such compounds to treat or prevent diseases and conditions in which the NLRP3 inflammasome is implicated. The specification further relates to compositions comprising such compounds.

##STR00001##

COMPOUNDS AND THEIR USE

The specification generally relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where R.sup.1, R.sup.2A, R.sup.2B, R.sup.2C, R.sup.2D, W, X, Y, and Z have the meanings defined herein. Such compounds are useful in inhibiting NLRP3 inflammasome activity and may be useful as therapeutic agents. The specification also relates to the use of such compounds to treat or prevent diseases and conditions in which the NLRP3 inflammasome is implicated. The specification further relates to compositions comprising such compounds.

##STR00001##

SMARCA INHIBITORS AND USES THEREOF
20230103415 · 2023-04-06 ·

The present invention provides compounds, compositions thereof, and methods of using the same.

BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME
20220315534 · 2022-10-06 ·

The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with an adrenergic receptor.

AZABICYCLIC(THIO)AMIDES AS FUNGICIDAL COMPOUNDS

The present invention relates to azabicyclic (thio)amide compounds and the uses thereof for controlling phytopathogenic microorganisms such as phytopathogenic fungi. It also relates to processes and intermediates for preparing these compounds

AZABICYCLIC(THIO)AMIDES AS FUNGICIDAL COMPOUNDS

The present invention relates to azabicyclic (thio)amide compounds and the uses thereof for controlling phytopathogenic microorganisms such as phytopathogenic fungi. It also relates to processes and intermediates for preparing these compounds

Aromatic compound, pharmaceutical composition and use thereof

The invention relates to an aromatic compound, pharmaceutical composition comprising the same, and a method for preparing the compound and an intermediate thereof. The invention also relates to use of the compound for the manufacture of a medicament for the prevention or treatment of a PPAR-related disease.

COMPOUNDS AND METHODS FOR TREATING AUTOIMMUNE DISORDERS BY TARGETING HLA-DQ2

Compounds and compositions useful in methods of treating, ameliorating, or inhibiting the development of an autoimmune disease by modulating the T cell response to antigenic peptide or fragments of antigenic peptides presented by the major histocompatibility (MHC) class II molecule, DQ2.